circulating tumor DNA
Advanced Cancer Outcomes Predicted Using Model Based on Circulating Tumor DNA Metrics
Researchers developed a ctDNA-based machine learning model for predicting metastatic non-small cell lung cancer response to immunotherapy and related survival outcomes.
Two methods for increasing the stability of cell-free DNA and for minimizing its cellular uptake could lead to higher cfDNA yields and improved cancer tests.
With $8 million in seed funding, Droplet is developing a test for minimal residual disease detection in head and neck cancer, with research ongoing for other promising targets.
Neogap Therapeutics, Simsen Diagnostics Collaborate on Cancer Dx
The companies will examine circulating tumor DNA in blood samples from patients participating in Neogap's Phase I/II clinical trial.
Personalis, AstraZeneca Extend Collaboration Around Residual Cancer Detection Test
Personalis will use its NeXT Personal molecular residual disease assay to track emerging recurrence in at least one AstraZeneca drug trial.